BRPI0513129A - método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo - Google Patents

método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo

Info

Publication number
BRPI0513129A
BRPI0513129A BRPI0513129-4A BRPI0513129A BRPI0513129A BR PI0513129 A BRPI0513129 A BR PI0513129A BR PI0513129 A BRPI0513129 A BR PI0513129A BR PI0513129 A BRPI0513129 A BR PI0513129A
Authority
BR
Brazil
Prior art keywords
hypogonadism
group
condition selected
treating
prostate cancer
Prior art date
Application number
BRPI0513129-4A
Other languages
English (en)
Inventor
Joseph Podolski
Ronald Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of BRPI0513129A publication Critical patent/BRPI0513129A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Método de Tratamento de Condição Selecionada do Grupo que Consiste em Hipertrofia Benigna da Próstata, Câncer de Próstata, Trigliceridos Elevados, Colesterol Alto e Hipogonadismo Podem ser usadas composições que compreendem transclomifeno no tratamento da hipertrofia benigna da próstata, câncer de próstata, níveis elevados de trigliceridos e hipogonadismo.
BRPI0513129-4A 2004-07-14 2005-07-14 método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo BRPI0513129A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58822304P 2004-07-14 2004-07-14
US58813004P 2004-07-14 2004-07-14
US58812304P 2004-07-14 2004-07-14
PCT/US2005/025000 WO2006019916A1 (en) 2004-07-14 2005-07-14 Trans-clomiphene for the treatment of benign prostate hypertrophy, prostate cancer, hypogonadism, elevated triglycerides and high cholesterol

Publications (1)

Publication Number Publication Date
BRPI0513129A true BRPI0513129A (pt) 2008-04-29

Family

ID=35134086

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513129-4A BRPI0513129A (pt) 2004-07-14 2005-07-14 método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo

Country Status (6)

Country Link
US (1) US20080242726A1 (pt)
EP (1) EP1776098A1 (pt)
BR (1) BRPI0513129A (pt)
EC (1) ECSP077247A (pt)
MX (1) MX2007000050A (pt)
WO (1) WO2006019916A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60228583D1 (de) 2001-07-09 2008-10-09 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
JP5785680B2 (ja) * 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
CA2702710C (en) * 2007-10-16 2013-05-07 Repros Therapeutics, Inc. Trans-clomiphene for metabolic syndrome
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
US20150202167A1 (en) 2012-08-21 2015-07-23 Repros Therapeutics Inc. Trans-Clomiphene Formulations and Uses Thereof
CA2889770A1 (en) * 2012-11-02 2014-05-08 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
US20160051495A1 (en) * 2014-08-20 2016-02-25 Professional Compounding Centers Of America Oral Transmucosal Compositions including C-SERMs for Low Testosterone Levels in Men
AU2017222567A1 (en) * 2016-02-25 2018-09-13 Aspen Park Pharmaceuticals, Inc. Oral dosage form of both clomiphene isomers and method of using same to treat secondary hypogonadism
CN108420806A (zh) * 2017-02-15 2018-08-21 武汉华杰世纪生物医药有限公司 具有靶向性的抗肿瘤药物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US6221399B1 (en) * 1995-08-17 2001-04-24 Csir Method of making controlled release particles of complexed polymers
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
JP2002511777A (ja) * 1996-10-28 2002-04-16 ゼネラル ミルズ，インコーポレイテッド 調放性粒子の埋包およびカプセル化
EP0973818B1 (en) * 1997-04-03 2004-10-13 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
ES2281186T3 (es) * 1998-08-07 2007-09-16 Novartis Vaccines And Diagnostics, Inc. Pirazoles como moduladores de receptores de estrogenos.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CO5180583A1 (es) * 1999-06-11 2002-07-30 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales a las mujeres
AU6132700A (en) * 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
BR0111141A (pt) * 2000-05-26 2003-04-08 Harry Fisch Métodos de tratar a deficiência de androgênio em homens e de tratar distúrbios relacionados com menopausa masculina nos homens
WO2002008546A1 (de) * 2000-07-22 2002-01-31 Hubertus Greschbach Modul zum aufbau von plattformen
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2431566A1 (en) * 2000-12-11 2002-07-18 Testocreme, Llc Topical testosterone formulations and associated methods
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
DE60228583D1 (de) * 2001-07-09 2008-10-09 Repros Therapeutics Inc Verfahren und materialien für die behandlung des testosteron-mangels bei männern
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) * 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators

Also Published As

Publication number Publication date
MX2007000050A (es) 2007-07-10
WO2006019916A1 (en) 2006-02-23
EP1776098A1 (en) 2007-04-25
ECSP077247A (es) 2007-03-29
US20080242726A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
BRPI0513129A (pt) método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo
BR0110084A (pt) Composições e métodos para melhorar saúde vascular
WO2007053573A3 (en) Treatment of cancer with sorafenib
PT1318837E (pt) Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
GB2440871A (en) Methods and compositions for delaying the release of treatment chemicals
NO20076401L (no) Diarylhydantoinforbindelser
MX2007003093A (es) Composiciones de tratamientos de lavanderia.
MX2009012951A (es) Composicion de recubrimiento que se puede curar por radiacion derivada de aceites vegetales epoxidados.
SV2009003227A (es) Composiciones de inhibidores de chk 1 ref. x-17672
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
ATE510553T1 (de) Beta-2-glycoprotein 1 als angiogenesehemmer
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2005110469A3 (en) Methods and compositions for reducing oxalate concentrations
DE50111057D1 (de) Hochverzweigte polymere zur antiknitterausrüstung von cellulosehaltigen textilien
WO2007021960A3 (en) Polymer compositions and processes for making and using same
WO2002030465A3 (en) Compositions that inhibit proliferation of cancer cells
WO2008063760A3 (en) Methods for treating cancer targeting transglutaminase
EP1584736A3 (en) Method for bleaching fibrous articles
NO20072336L (no) Biologisk nedbrytbar, superabsorberende blanding samt fremgangsmåte for å hindre sirkulasjonstap i brønn
WO2006015191A3 (en) Multicyclic lonidamine analogs
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
MXPA05012780A (es) Metodo para tratar estructuras fibrosas.
WO2004069148A3 (en) Snornai-small nucleolar rna degradation by rna interference in trypanosomatids
WO2008115478A3 (en) Method of cancer detection and treatment
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO NO 020130047159/RJ DE 29.05.2013, EM VIRTUDE DO DISPOSTO NO ARTIGO 219 INCISO II DA LPI NO 9.279/96, UMA VEZ QUE NAO HA FUNDAMENTACAO LEGAL.

B151 Others concerning applications: resolution cancelled

Free format text: ANULADO O DESPACHO 15.7 DA RPI 2224 DE 20/08/2013, POR TER SIDO INDEVIDO.